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A B S T R A C T
Background: The immunogenicity proﬁle of the 9-valent HPV (9vHPV) vaccine was evaluated across
ﬁve phase III clinical studies conducted in girls and boys 9–15 years of age and young women 16–26 years
of age. The eﬀect of baseline characteristics of subjects on vaccine-induced HPV antibody responses was
assessed.
Methods: Immunogenicity data from 11,304 subjects who received ≥1 dose of 9vHPV vaccine in ﬁve Phase III
studies were analyzed. Vaccine was administered as a 3-dose regimen. HPV antibody titers were assessed
1 month after dose 3 using a competitive Luminex immunoassay and summarized as geometric mean
titers (GMTs). Covariates examined were age, gender, race, region of residence, and HPV serostatus and PCR
status at day 1.
Results: GMTs to all 9 vaccine HPV types decreased with age at vaccination initiation, and were
otherwise generally similar among the demographic subgroups deﬁned by gender, race and region of residence.
For all subgroups deﬁned by race or region of residence, GMTs were higher in girls and boys than in young
women. Vaccination of subjects who were seropositive at day 1 to a vaccine HPV type resulted in higher GMTs
to that type, compared with those in subjects who were seronegative for that type at day 1.
Conclusions: 9vHPV vaccine immunogenicity was robust among subjects with diﬀering baseline characteristics.
It was generally comparable across subjects of diﬀerent races and from diﬀerent regions. Greater immuno-
genicity in girls and boys versus young women (the population used to establish 9vHPV vaccine eﬃcacy in
clinical studies) indicates that the anti-HPV responses generated by the vaccine in adolescents from all races or
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regions were suﬃcient to induce high-level protective eﬃcacy. This immunogenicity proﬁle supports a
widespread 9vHPV vaccination program and early vaccination.
1. Introduction
Human papillomavirus (HPV) is the cause of nearly all cervical
cancers and a substantial proportion of anal, vulvar, vaginal, penile and
oropharyngeal cancers; thus, it is responsible of approximately 5% of
the global cancer burden [1]. The identiﬁcation of HPV as a primary
cause of anogenital cancers created an opportunity for cancer preven-
tion through vaccination. First generation HPV vaccines, including the
quadrivalent HPV (types 6/11/16/18) (qHPV) vaccine and the bivalent
HPV (types 16/18) vaccine were initially developed [2]. A 9-valent HPV
(types 6/11/16/18/31/33/45/52/58) (9vHPV) vaccine (Gardasil 9,
Merck & Co., Inc., Kenilworth, NJ) was subsequently developed to
provide protection against the HPV types already covered by the qHPV
vaccine and the next ﬁve most common oncogenic types associated
with cervical cancer worldwide (types 31/33/45/52/58) [3]. The
9vHPV vaccine could potentially prevent approximately 90% of cervical
cancers, HPV-related vulvar, vaginal and anal cancers and genital warts
worldwide [4–9]. The 9vHPV vaccine was licensed in 2014 in the US,
in 2015 in Canada, the EU and Australia, and in 2015 and 2016 in
other countries.
In a clinical trial conducted in women 16–26 years of age, the
9vHPV vaccine prevented infection and disease caused by HPV 31/33/
45/52/58. It also induced anti-HPV 6/11/16/18 antibody responses
that were non-inferior to responses induced by the qHPV vaccine;
eﬃcacy of the 9vHPV vaccine against infection and disease caused by
HPV 6/11/16/18 was inferred based on these results [10–12]. In
another clinical trial, the 9vHPV vaccine induced non-inferior antibody
responses to HPV 6/11/16/18/31/33/45/52/58 in girls and boys 9–15
years of age vs. women 16–26 years of age; eﬃcacy of the 9vHPV
vaccine against infection and disease caused by the 9 vaccine HPV
types in girls and boys 9–15 years of age was inferred based on these
results [13].
HPV infection is a global health concern; prophylactic HPV
vaccination is included in the national immunization programs of at
least 80 countries [14], and used in diverse settings worldwide. It is
anticipated that the 9vHPV vaccine will be widely licensed and
recommended. Thus, it is useful to evaluate the impact of demographic
parameters on the immunogenicity of the 9vHPV vaccine. Of relevant
note, a similar study examining the impact of demographic parameters
on the immunogenicity of the qHPV vaccine was published shortly after
the initial licensure of the qHPV vaccine [15]. This report summarizes a
combined analysis of ﬁve Phase III clinical trials conducted in girls and
boys 9–15 years of age and women 16–26 years of age to examine
antibody responses in subgroups for which individual studies may have
had limited sample size. Thus, these analyses are novel and may be of
interest to many as the 9vHPV vaccine becomes more widely available.
Immunogenicity of the 9vHPV vaccine in young men 16–26 years of
age was not included in these analyses; it will be the topic of another
report so that the additional complexities speciﬁc to that population
(i.e., lower HPV antibody responses in men having sex with men than
in heterosexual men [16,17]) can be fully explored.
2. Materials and methods
2.1. Enrollment and vaccination
An analysis of the combined immunogenicity database of Phase III
studies submitted to regulatory agencies in support of the licensure of
the 9vHPV vaccine was conducted. This analysis included 11,304
subjects who received 9vHPV vaccine in ﬁve Phase III studies
(Table 1). These studies contained three separate populations: virginal
girls 9–15 years of age, virginal boys 9–15 years of age, and young
women 16–26 years of age, most of whom were sexually active. Eligible
subjects received a 3-dose vaccination regimen given as intramuscular
injections at day 1, month 2 and month 6. Each study was conducted in
accordance with principles of Good Clinical Practice and was approved
by the institutional review board at each participating institution and
by regulatory agencies. Written informed consent was provided by all
adult subjects and by a parent or legal guardian of subjects who were
minors, assent was also obtained from minors in conformity with
Table 1
Phase III studies of the 9vHPV vaccine contributing to the combined immunogenicity analysis.
Study Key objectives Experimental arm Control arm Included in
analysesa
001 Immunogenicity, efficacy vs. qHPV Women age 16–26 years randomized to 9vHPV
vaccine (N=6799)b
Women age 16–26 years randomized to qHPV
vaccine (N=6799)b
N=6792b,c
002 Adult-to-adolescent
immunobridging
Girls and boys age 9–15 years (N=2604) enrolled to
receive 9vHPV vaccine
Women age 16–26 years enrolled to receive
9vHPV vaccine (N=470)
N=3066
005 Co-administration with Menactra/
Adacel
Girls and boys age 11–15 years randomized to
concomitant arm (N=621)
Girls and boys age 11–15 years randomized to
non-concomitant arm (N=620)
N=618d
007 Co-administration with Repevax Girls and boys age 11–15 years randomized to
concomitant arm (N=526)
Girls and boys age 11–15 years randomized to
non-concomitant arm (N=528)
N=528d
009 qHPV-to-9vHPV immunobridging Girls age 9–15 years randomized to 9vHPV vaccine
(N=300)
Girls age 9–15 years randomized to qHPV
vaccine (N=300)
N=300c
Study 001: NCT00543543 [10].
Study 002: NCT00943722 [13].
Study 005: NCT00988884 [22].
Study 007: NCT01073293 [23].
Study 009/GDS01C: NCT01304498 [12].
a Subjects who received at least one vaccination with 9vHPV vaccine. A total of 11,304 subjects who received at least one 9vHPV vaccination are included in these analyses. Most
subjects (97.7% [11,046 of 11,304]) received the three vaccinations.
b Subjects who received the low-dose, mid-dose or high-dose formulation of 9vHPV vaccine during the dose selection portion of the study [10,43] are not included; immunogenicity
results in these subjects are reported in [44].
c Subjects randomized to the 9vHPV vaccine who received ≥1 dose of vaccine.
d Subjects randomized to the non-concomitant arm who received ≥1 dose of 9vHPV vaccine. Subjects randomized to the concomitant arm of studies 005 and 007 are not considered in
this report; immunogenicity results in these subjects are reported in [22,23].
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applicable national and local requirements. Baseline characteristics for
the overall population of subjects who were randomized to receive the
9vHPV vaccine are presented in Table 2.
2.2. Immunogenicity evaluation
Serum samples were obtained at day 1 and month 7 for anti-HPV
antibody testing. The serum samples were assessed for antibodies to
HPV VLP types 6/11/16/18/31/33/45/52/58 by a multiplexed com-
petitive Luminex Immunoassay (cLIA; HPV-9 cLIA Version 2.0;
performed by PPD Vaccines and Biologics Lab, Wayne, PA, USA), as
described previously [18]. Antibody titers for each individual HPV type
were determined through competition with type-speciﬁc monoclonal
antibodies, so it is not possible to directly compare assay results across
HPV types. In addition, cervical and external genital swabs collected at
day 1 and month 7 in young women 16–26 years of age for testing by
polymerase chain reaction (PCR) for type-speciﬁc detection of HPV
DNA; PCR testing included the 9 vaccine types and 5 additional
oncogenic HPV types (HPV 35/39/51/56/59)[19,20]. HPV seroposi-
tivity at day 1 or PCR positivity at day 1 and month 7 was not a reason
for exclusion from the study; however, the results were part of the
criteria to deﬁne analysis populations.
2.3. Data analysis
The serum samples from day 1 and PCR samples from day 1 and
month 7 were analyzed for each vaccine HPV type prior to enrollment
to identify participants who were positive to one or more HPV types,
and these participants were subsequently excluded from the per-
protocol immunogenicity analysis for the corresponding HPV type(s).
To be included in the HPV type speciﬁc per-protocol immunogenicity
analysis populations, subjects had to meet the following requirements:
(1) be seronegative at day 1 and (for 16- to 26-year-old women) PCR-
negative from day 1 through month 7 only for the HPV type being
analyzed (for HPV 6 and HPV 11 immunogenicity analyses, because of
extensive cross-reactivity due to the high amino acid sequence identity
[92%] between HPV 6 and HPV 11 L1 proteins [21], subjects had to be
seronegative and, for women 16–26 years of age, PCR-negative for
both HPV 6 and HPV 11); (2) receive all 3 doses of the correct clinical
material within acceptable day ranges; (3) have a post-dose 3 serology
result within acceptable day ranges and (4) have no protocol violation
that could potentially interfere with the immunogenicity evaluation as
judged by the study director. Seropositive was deﬁned as anti-HPV
serum cLIA levels ≥30, 16, 20, 24, 10, 8, 8, 8, 8 milli-Merck units per
milliliter (mMU/mL) for HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58
respectively. Subjects who incidentally received a concomitant vaccina-
tion in studies 001, 002 and 009, were excluded from per-protocol
immunogenicity analyses as concomitant vaccination was prohibited
per protocol in these studies [10,12,13]. Thus, for consistency across
studies, subjects in the concomitant arm of studies 005 and 007
(studies to assess co-administration of 9vHPV vaccine with diphtheria,
tetanus, pertussis, poliomyelitis and meningococcal vaccines) were also
excluded from this combined immunogenicity analysis.
Immunogenicity results from the concomitant and non-concomitant
arms of studies 005 and 007 have been reported [22,23]. Subjects
excluded from per-protocol analyses are summarized in Supplementary
material Table 1. Although the per-protocol analyses excluded subjects
who were HPV positive (seropositive and/or PCR positive) for vaccine
HPV types at baseline, a separate analysis was performed including
these subjects to elucidate the diﬀerences in immune response between
baseline HPV positive and HPV negative subjects. To be included in
this analysis, subjects had to meet the following requirements: (1) have
a day 1 serology result and a day 1 PCR result; (2) receive all 3 doses of
the correct clinical material; and (3) have a post-dose 3 serology result
within acceptable day ranges. These analyses were done in subjects
(women 16–26 years) enrolled in study 001.
Geometric mean titers (GMTs) with associated 95% conﬁdence
intervals were computed and compared across categories of baseline
subject characteristics. Cohorts analyzed included subjects given the
9vHPV vaccine stratiﬁed into the following three age/sex groups: boys
9–15 years of age, girls 9–15 years of age, and young women 16–26
years of age. Baseline covariates analyzed included age, sex, race, region
of residence, and baseline HPV seropositivity and PCR-positivity. All of
these evaluations were exploratory in nature; therefore, no statistical
tests of hypotheses were performed. Non overlapping 95% conﬁdence
intervals were used as indicators of diﬀerences of immune response.
It has been previously observed that HPV antibody response to HPV
vaccination declines with increasing age [2,13,15]. Analyses were con-
ducted to explore whether this relationship varies with race and geo-
graphic region. Linear regression model was ﬁtted on the logarithm (base
10) of HPV antibody titer at Month 7 as a function of age at vaccination
dose 1 to model the relationship of HPV antibody response at Month 7
with age. Graphical methods were used to display the regression line
representing the estimated mean log10-HPV antibody response as a
function of age together with the 95% conﬁdence band around the
regression line. The regression line and 95% conﬁdence band were
displayed by race and geographic region to graphically compare trends
of the relationship of HPV antibody response by age across race and
geographic region. For each HPV type, two analyses were conducted: an
analysis of mean HPV antibody response by race irrespective of geo-
graphic region (this analysis is relevant given that race is a reasonable
surrogate for geographic region); a second analysis of mean HPV antibody
response by race and geographic region. No formal statistical testing was
done on the trends of the relationship of mean HPV antibody response by
age across race or race and geographic region.
In studies 001 and 009, subjects were randomized to receive 9vHPV
vaccine or qHPV vaccine [10,12]. This report considers only subjects
who received the 9vHPV vaccine. Immunogenicity of qHPV vaccine by
baseline covariates has already been reported [15].
Table 2
Subject characteristics (all randomized subjects).
Females 9–15 years
of age
Males 9–15 years
of age
Females 16–26
years of age
n (%) n (%) n (%)
Subjects in
population
2809 1243 7269
Age (years)
Subjects with
data
2809 1243 7269
Mean 12 12 22
SD 2 2 2
Median 12 12 22
Range 9 to 15 9 to 15 16 to 26
Race
Asian 470 (16.7) 224 (18.0) 1113 (15.3)
Black 182 (6.5) 60 (4.8) 281 (3.9)
White 1749 (62.3) 665 (53.5) 4004 (55.1)
Othera 408 (14.5) 294 (23.7) 1871 (25.7)
Region
Africa 95 (3.4) 30 (2.4) 40 (0.6)
Asia-Paciﬁc 458 (16.3) 219 (17.6) 998 (13.7)
Europe 1102 (39.2) 373 (30.0) 2531 (34.8)
Latin America 545 (19.4) 286 (23.0) 2319 (31.9)
North America 609 (21.7) 335 (27.0) 1381 (19.0)
Study participants were from 26 countries (Austria, Belgium, Brazil, Canada, Chile,
Colombia, Costa Rica, Denmark, Finland, Germany, Hong Kong, India, Italy, Japan,
Korea, Mexico, New Zealand, Norway, Peru, Poland, South Africa, Spain, Sweden,
Taiwan, Thailand, and the United States [including Puerto Rico]).
a The category 'Other' for the race variable includes Multi-Racial, American Indian or
Alaska Native, Native Hawaiian or Paciﬁc Islander, Unknown and missing race
information. Most subjects in that category are Multi-Racial.
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3. Results
The population included in the present analysis was ethnically diverse
and resided in both high-income and low- and middle-income countries.
The baseline characteristics among the age/sex cohorts are shown in
Table 2. Overall, 98.8% (11,304 of 11,321) of subjects randomized to
9vHPV vaccine received at least one dose of vaccine and 97.6% (11,046 of
11,321) of subjects received all three doses of vaccine. Principal reasons
for exclusion from per-protocol immunogenicity analyses included
seropositivity and/or PCR positivity to HPV vaccine types and missing
serology samples (Supplementary material Table 1).
Table 3 summarizes the serum anti-HPV responses at month 7 in
the three populations analyzed. For all subjects, seroconversion rates at
month 7 ranged from 99.6% to 100%. As seen previously in study 002
[13], geometric mean titers (GMTs) at month 7 were markedly higher
in girls and boys than in young women for all 9 vaccine HPV types; and
among the adolescents, administration of the vaccine to boys generally
resulted in marginally higher anti-HPV GMTs than girls of the same
age. Fig. 1 summarizes the serum anti-HPV responses at month 7 in
girls and women, stratiﬁed by age at enrollment. GMTs decreased with
increasing age. Relatively large variations for ages 16 and 17 years were
observed, likely representing random variations due to the limited
numbers of subjects enrolled in this age range (~2% of total girls and
women enrollment). Supplementary material Fig. 1 provides a similar
analysis for boys. For each of the 9 HPV types, month 7 GMTs
decreased as the age at ﬁrst vaccination increased.
Small numeric diﬀerences in month 7 anti-HPV GMTs were
observed among subpopulations of women 16–26 years of age deﬁned
by race. In particular, black women tended to have higher anti-HPV
GMTs than Asian or white women or women of other races. However,
no consistent pattern was demonstrated across all 9 vaccine types
(Table 4). Subjects in Africa, Latin America and North America tended
to have higher anti-HPV GMTs than subjects in Asia, and Europe
(Table 5). Analyses of month 7 GMTs by race (Supplementary material
Tables 2 and 3) and by region (Supplementary material Tables 4 and 5)
in girls and boys 9–15 years of age provided similar results. Month 7
GMTs were markedly higher in girls and boys 9–15 years of age than in
women 16–26 years of age for all subgroups deﬁned by race or region
for all 9 HPV types.
In exploratory analyses, the inverse relationship between mean
HPV antibody responses at month 7 and age was seen regardless of
race and geographic region (Supplementary material Fig. 2). Even
though small diﬀerences were observed among subgroups deﬁned by
race or race and region, no consistent pattern was demonstrated across
all 9 vaccine types.
Table 6 displays the anti-HPV levels at month 7 in subject groups
Table 3
Per-protocol summary of month 7 anti-HPV geometric mean titers in subjects who received 3 doses of 9vHPV vaccine.
Population N n % Seropositive (95% CI) GMT (95% CI)
Anti-HPV 6
9- through 15-year-old girls 2805 2349 99.7 (99.4, 99.9) 1744.6 (1684.7, 1806.7)
9- through 15-year-old boys 1239 1055 99.9 (99.5, 100) 2085.3 (1984.2, 2191.6)
16- through 26-year-old women 7260 4321 99.8 (99.6, 99.9) 893.7 (873.5, 914.3)
Anti-HPV 11
9- through 15-year-old girls 2805 2350 99.9 (99.7, 100) 1289.7 (1244.3, 1336.8)
9- through 15-year-old boys 1239 1055 100 (99.7, 100) 1469.2 (1397.7, 1544.4)
16- through 26-year-old women 7260 4327 100 (99.9, 100) 669.3 (653.6, 685.4)
Anti-HPV 16
9- through 15-year-old girls 2805 2405 99.9 (99.7, 100) 7159.9 (6919.7, 7408.5)
9- through 15-year-old boys 1239 1076 100 (99.7, 100) 8444.9 (8054.2, 8854.5)
16- through 26-year-old women 7260 4361 100 (99.9, 100) 3159.0 (3088.6, 3231.1)
Anti-HPV 18
9- through 15-year-old girls 2805 2420 99.9 (99.6, 100) 2085.5 (2002.2, 2172.3)
9- through 15-year-old boys 1239 1074 100 (99.7, 100) 2620.4 (2474.3, 2775.2)
16- through 26-year-old women 7260 4884 99.8 (99.7, 99.9) 809.9 (789.2, 831.1)
Anti-HPV 31
9- through 15-year-old girls 2805 2397 100 (99.8, 100) 1883.3 (1811.3, 1958.1)
9- through 15-year-old boys 1239 1069 100 (99.7, 100) 2173.5 (2057.0, 2296.6)
16- through 26-year-old women 7260 4806 99.8 (99.6, 99.9) 664.8 (647.4, 682.6)
Anti-HPV 33
9- through 15-year-old girls 2805 2418 99.9 (99.7, 100) 960.6 (927.5, 994.9)
9- through 15-year-old boys 1239 1076 100 (99.7, 100) 1178.6 (1120.9, 1239.4)
16- through 26-year-old women 7260 5056 99.7 (99.5, 99.8) 419.2 (409.6, 429.1)
Anti-HPV 45
9- through 15-year-old girls 2805 2430 99.8 (99.6, 100) 728.7 (697.6, 761.2)
9- through 15-year-old boys 1239 1079 100 (99.7, 100) 841.7 (790.0, 896.7)
16- through 26-year-old women 7260 5160 99.6 (99.4, 99.7) 254.1 (247.0, 261.5)
Anti-HPV 52
9- through 15-year-old girls 2805 2426 99.9 (99.7, 100) 978.2 (942.8, 1015.0)
9- through 15-year-old boys 1239 1077 100 (99.7, 100) 1062.2 (1007.2, 1120.2)
16- through 26-year-old women 7260 4792 99.8 (99.6, 99.9) 382.4 (373.0, 392.0)
Anti-HPV 58
9- through 15-year-old girls 2805 2397 99.9 (99.7, 100) 1306.0 (1259.8, 1354.0)
9- through 15-year-old boys 1239 1072 100 (99.7, 100) 1545.8 (1470.6, 1624.8)
16- through 26-year-old women 7260 4818 99.8 (99.6, 99.9) 489.2 (477.5, 501.2)
N=number of individuals randomized to the respective vaccination group who received at least 1 injection.
n=number of individuals contributing to the analysis.
mMU=milli-Merck units.
CI=confidence interval.
GMT=geometric mean titers (given in milli-Merck units per milliliter).
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Fig. 1. Plots of month 7 anti-HPV geometric mean titers (GMTs) responses in females to component human papillomavirus (HPV) vaccine types, by age at enrollment. GMTs with
associated 95% conﬁdence intervals are presented for the per-protocol immunogenicity population. cLIA, competitive Luminex-based immunoassay; mMU, milli-Merck units.
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deﬁned by day 1 HPV serostatus and PCR status. Inclusion of subjects
regardless of baseline HPV status permitted a comparison of vaccine-
induced immune responses with those generated in response to an
HPV infection. Robust antibody responses were observed in all groups
for all HPV types. GMTs appeared to be the highest in the group which
was seropositive and PCR negative on day 1 (i.e., subjects who were
seropositive at enrollment likely due to a prior exposure to HPV).
GMTs were analyzed over time in the per-protocol population and
in subjects seropositive and PCR negative at day 1 in study 001. Table 7
enumerates anti-HPV GMTs at all time- points from month 3 (1 month
post-dose 2) and month 7 (1 month post-dose 3) to month 42 in
subjects that were seropositive and PCR negative at day 1. Notably, in
Table 4
Per-protocol summary of anti-HPV geometric mean titers at month 7 by race in women 16–26 years of age who received 3 doses of 9vHPV vaccine.
Race
Asian Black White Other
Assay n GMT
(95% CI)
n GMT
(95% CI)
n GMT
(95% CI)
n GMT
(95% CI)
HPV 6 763 837.4
(793.1,
884.0)
123 935.3
(817.1,
1070.6)
2415 895.4
(868.5,
923.1)
1020 929.0
(886.5,
973.7)
HPV 11 764 594.5
(561.9,
629.0)
122 670.1
(581.8,
771.7)
2421 691.1
(669.5,
713.3)
1020 677.7
(645.4,
711.6)
HPV 16 792 3071.2
(2913.4,
3237.7)
152 3983.9
(3531.7,
4493.9)
2361 3077.8
(2985.2,
3173.4)
1056 3307.7
(3159.9,
3462.3)
HPV 18 831 850.9
(799.4,
905.7)
170 995.0
(866.8,
1142.3)
2669 755.6
(729.7,
782.3)
1214 886.2
(841.6,
933.2)
HPV 31 858 710.7
(667.6,
756.6)
169 786.4
(683.0,
905.5)
2631 619.5
(597.8,
642.1)
1148 725.1
(686.9,
765.4)
HPV 33 856 420.2
(397.1,
444.6)
189 414.6
(367.6,
467.5)
2733 417.1
(404.1,
430.5)
1278 424.0
(404.8,
444.0)
HPV 45 885 281.4
(262.9,
301.3)
190 345.0
(297.9,
399.6)
2824 227.3
(218.8,
236.1)
1261 290.1
(274.1,
307.2)
HPV 52 788 353.8
(332.7,
376.1)
166 444.0
(388.4,
507.5)
2690 388.2
(375.6,
401.4)
1148 381.0
(362.1,
400.8)
HPV 58 814 520.3
(490.5,
551.9)
161 493.1
(431.9,
562.9)
2720 483.6
(468.2,
499.4)
1123 480.8
(457.2,
505.5)
GMT, geometric mean titer (given in milli-Merck units per milliliter). CI, confidence interval.
Table 5
Per-protocol summary of month 7 anti-HPV geometric mean titers by region in women 16–26 years of age who received 3 doses of 9vHPV vaccine.
Region
Africa Asia-Paciﬁc Europe Latin America North America
Assay n GMT (95% CI) n GMT (95% CI) n GMT (95% CI) n GMT (95% CI) n GMT (95% CI)
HPV 6 16 1029.5
(708.5, 1496.1)
691 817.9
(772.7, 865.8)
1454 850.9
(818.2, 884.9)
1292 946.6
(908.1, 986.8)
868 953.2
(906.1, 1002.8)
HPV 11 15 764.4
(511.2, 1142.9)
692 588.9
(555.0, 624.8)
1458 660.0
(633.7, 687.5)
1292 686.0
(656.9, 716.4)
870 729.5
(692.0, 769.1)
HPV 16 20 5218.2
(3746.9, 7267.3)
722 2943.1
(2785.2, 3109.8)
1412 2929.3
(2816.1, 3047.1)
1336 3355.0
(3221.8, 3493.8)
871 3412.8
(3245.7, 3588.5)
HPV 18 21 1376.9
(930.3, 2037.7)
758 827.4
(775.1, 883.2)
1604 714.2
(682.9, 747.0)
1537 887.6
(847.9, 929.2)
964 838.4
(791.3, 888.3)
HPV 31 23 986.1
(673.5, 1443.9)
785 673.6
(631.0, 719.0)
1584 578.7
(552.7, 605.9)
1454 725.5
(691.6, 761.2)
960 717.3
(676.1, 760.9)
HPV 33 18 442.9
(300.3, 653.3)
782 407.1
(383.8, 431.9)
1635 396.9
(381.1, 413.4)
1616 429.3
(412.0, 447.3)
1005 450.9
(428.1, 475.0)
HPV 45 24 518.1
(343.1, 782.3)
810 267.7
(249.4, 287.4)
1714 207.8
(197.9, 218.2)
1604 291.0
(276.7, 306.1)
1008 272.0
(255.2, 289.8)
HPV 52 20 552.8
(376.5, 811.7)
717 340.6
(319.4, 363.2)
1620 365.1
(349.8, 381.0)
1465 390.8
(373.7, 408.8)
970 432.1
(409.0, 456.7)
HPV 58 15 706.9
(458.1, 1090.8)
743 497.3
(467.5, 528.9)
1647 468.2
(449.2, 487.9)
1425 482.8
(461.7, 504.7)
988 527.2
(499.8, 556.1)
GMT, geometric mean titer (given in milli-Merck units per milliliter). CI, confidence interval.
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this population, the anti-HPV GMTs generated by the 9vHPV vaccine
were dramatically increased after 2 doses (month 3) or 3 doses (month
7), and were substantially higher (as evidenced by non-overlapping
95% CI) than GMTs observed in the per-protocol population for all
time points from month 3 to month 42.
4. Discussion
A combined analysis of the immunogenicity in ﬁve Phase III clinical
studies showed that a 3-dose regimen of the 9vHPV vaccine was highly
immunogenic in girls and boys 9–15 years of age and young women
16–26 years of age, with seroconversion rates at 1 month post-dose 3 >
99% in these three populations. GMTs at 1 month post-dose 3 in the
combined database were higher in girls and boys than in young women,
a ﬁnding consistent with results previously seen in study 002 [13].
Moreover, the 9vHPV vaccine induced robust HPV antibody responses
to all 9 vaccine HPV types in all subgroups of subjects deﬁned by age,
race, and geographic region of residence. GMTs at 1 month post-dose 3
steadily decreased with increasing age at the start of vaccination. Small
numeric diﬀerences in GMTs were observed among subpopulations
deﬁned by race and region of residence. In groups of subjects who were
seropositive and PCR negative for a given HPV type at day 1, higher
GMTs were seen for this HPV type compared with groups of subjects
who were seronegative for this HPV type at day 1. HPV seropositivity at
baseline likely reﬂects a humoral immune response following prior
infection with HPV; PCR negativity likely indicates the absence of
ongoing infection with HPV. The higher GMTs in this population are
suggestive of an anamnestic response following 9vHPV vaccine admin-
istration [24]. Recently, Scherer et al. reported that a single dose of the
qHPV vaccine improved the B cell memory of persons with pre-existing
antibodies to HPV 16. In this study, a single dose of qHPV vaccine
administered to HPV 16-seropositive women boosted antibody levels
24- to 930-fold at one month post-vaccination and elicited HPV 16-
speciﬁc memory B cells that expressed type speciﬁc neutralizing
antibodies [25]. These data indicate that vaccination augments natural
HPV immunity by not only boosting antibody levels but also eliciting a
quantitatively and qualitatively superior memory B cell response. Of
note, the qHPV vaccine has been shown to protect seropositive women
against subsequent disease due to the corresponding vaccine HPV type
[26]. Taken together these results indicate that in subjects previously
infected with certain HPV vaccine types and who have cleared
infection, vaccination could potentially prevent reinfection and disease
due to these types. It must be noted though, regardless of the HPV
seropositivity status prior to vaccination, all subjects exhibited a robust
boost in GMTs post-vaccination.
In a Phase III clinical study (study 001), the 9vHPV vaccine
prevented infection and disease related to HPV 31/33/45/52/58 in
young women 16–26 years of age from multiple races and regions [10].
In the same study, the eﬃcacy ﬁndings established with qHPV vaccine
for HPV 6/11/16/18 in earlier clinical studies [27–29] were extended
Table 6
Month 7 anti-HPV geometric mean titers by day 1 serostatus and PCR status in women, 16–26 years of age who completed the 3-dose 9vHPV vaccine regimena.
Females 16–26 years of age (N=7260)
HPV type Day 1 serostatus Day 1 PCR status n GMT (mMU/mL) (95% CI)
HPV 6 Negative Negative 4720 901.4 (881.8, 921.4)
Negative Positive 113 1025.2 (881.8, 1192.0)
Positive Negative 807 1876.0 (1742.2, 2020.1)
Positive Positive 109 1509.5 (1287.3, 1770.1)
HPV 11 Negative Negative 4723 675.7 (660.3, 691.4)
Negative Positive 13 618.4 (331.1, 1155.3)
Positive Negative 188 1065.9 (935.0, 1215.0)
Positive Positive 14 1110.9 (652.9, 1890.2)
HPV 16 Negative Negative 4799 3177.3 (3109.4, 3246.7)
Negative Positive 323 2941.4 (2676.1, 3233.1)
Positive Negative 492 5248.6 (4848.6, 5681.5)
Positive Positive 260 4374.0 (3968.9, 4820.6)
HPV 18 Negative Negative 5334 815.9 (796.0, 836.3)
Negative Positive 178 941.2 (829.7, 1067.7)
Positive Negative 266 1917.2 (1714.3, 2144.0)
Positive Positive 86 1472.5 (1236.3, 1753.8)
HPV 31 Negative Negative 5254 668.2 (651.5, 685.3)
Negative Positive 184 625.3 (553.5, 706.4)
Positive Negative 327 964.4 (877.3, 1060.1)
Positive Positive 112 798.5 (690.3, 923.7)
HPV 33 Negative Negative 5503 424.1 (414.8, 433.7)
Negative Positive 101 443.3 (375.7, 523.1)
Positive Negative 215 665.7 (582.5, 760.7)
Positive Positive 59 616.0 (482.4, 786.7)
HPV 45 Negative Negative 5620 255.0 (248.1, 262.0)
Negative Positive 130 256.9 (216.8, 304.4)
Positive Negative 82 354.0 (279.1, 449.1)
Positive Positive 29 285.8 (195.7, 417.4)
HPV 52 Negative Negative 5259 385.1 (376.1, 394.3)
Negative Positive 275 303.5 (272.8, 337.5)
Positive Negative 220 547.1 (488.5, 612.7)
Positive Positive 121 319.8 (271.4, 376.7)
HPV 58 Negative Negative 5267 493.8 (482.5, 505.4)
Negative Positive 158 423.3 (376.1, 476.3)
Positive Negative 373 618.9 (559.6, 684.6)
Positive Positive 82 669.8 (548.4, 818.0)
N=number of subjects who received at least 1 injection of 9vHPV vaccine; n=number of subjects contributing to the analysis.
GMT, geometric mean titer (given in milli-Merck units per milliliter). CI, confidence interval.
a This analysis population includes subjects who received all 3 doses of correct clinical material, had serology & PCR results at day 1 for the relevant HPV type and had a post-dose 3
or month 7 serology result within acceptable day ranges.
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Table 7
Month 7 anti-HPV geometric mean titers in women, 16–26 years of age who completed the 3-dose 9vHPV vaccine regimen in study 001.
Per protocol immunogenicity population Day 1 seropositive and PCR-negative
Assay
time point
n GMT (95% CI) n GMT (95% CI)
HPV 6
Day 1 3993 < 16 ( < 16, < 16) 917 108.1 (102.2, 114.3)
Month 3 788 734.0 (692.8, 777.7) 188 2384.0 (1982.9, 2866.1)
Month 7 3993 893.1 (871.7, 915.1) 752 1874.8 (1737.6, 2022.8)
Month 12 800 330.6 (312.2, 350.1) 213 951.9 (807.3, 1122.3)
Month 24 715 208.6 (195.5, 222.7) 182 634.3 (529.6, 759.8)
Month 36 685 163.9 (153.0, 175.6) 155 462.9 (382.5, 560.2)
Month 42 692 147.2 (137.3, 157.8) 163 444.1 (369.2, 534.3)
HPV 11
Day 1 3995 < 6 ( < 6, < 6) 208 44.6 (39.2, 50.8)
Month 3 790 529.1 (499.7, 560.1) 44 1666.4 (1229.9, 2257.9)
Month 7 3995 666.3 (649.6, 683.4) 175 1050.2 (914.9, 1205.6)
Month 12 810 212.4 (200.1, 225.6) 49 609.9 (465.7, 798.9)
Month 24 763 123.3 (115.8, 131.2) 40 360.7 (264.9, 491.0)
Month 36 690 89.6 (83.3, 96.3) 35 214.4 (149.4, 307.7)
Month 42 696 84.9 (79.0, 91.3) 34 201.9, (140.6, 289.8)
HPV 16
Day 1 4032 < 12 ( < 12, < 12) 564 126.6 (115.1, 139.3)
Month 3 794 2435.8 (2303.5, 2575.6) 104 7064.1 (5775.9, 8639.7)
Month 7 4032 3131.1 (3057.1, 3206.9) 458 5149.6 (4752.9, 5579.5)
Month 12 819 1041.7 (979.9, 1107.4) 134 3079.9 (2582.1, 3673.6)
Month 24 778 520.7 (484.7, 559.4) 98 1824.4 (1436.6, 2316.9)
Month 36 695 386.5 (356.3, 419.4) 82 1228.6 (939.5, 1606.6)
Month 42 709 346.8 (319.3, 376.7) 90 1186.7 (934.8, 1506.4)
HPV 18
Day 1 4539 < 8 ( < 8, < 8) 296 83.0 (74.3, 92.8)
Month 3 908 470.8 (442.8, 500.7) 58 1920.1 (1464.2, 2517.9)
Month 7 4539 804.6 (782.7, 827.1) 241 1883.4 (1670.6, 2123.4)
Month 12 929 198.6 (184.9, 213.4) 72 1012.7 (773.7, 1325.6)
Month 24 886 86.0 (79.0, 93.6) 52 537.2 (390.1, 739.8)
Month 36 789 78.5 (71.9, 85.6) 48 397.0 (285.8, 551.5)
Month 42 806 70.8 (64.8, 77.3) 47 374.9 (268.6, 523.2)
HPV 31
Day 1 4466 < 4 ( < 4, < 4) 373 38.7 (35.0, 42.6)
Month 3 881 437.6 (406.7, 470.8) 83 825.6 (609.4, 1118.4)
Month 7 4466 658.4 (636.7, 680.9) 295 952.8 (831.5, 1091.8)
Month 12 909 196.5 (183.5, 210.4) 90 452.2 (340.3, 600.8)
Month 24 863 101.9 (94.9, 109.5) 71 242.0 (174.5, 335.6)
Month 36 772 72.7 (67.5, 78.4) 62 182.1 (128.4, 258.4)
Month 42 783 70.4 (65.3, 75.9) 68 163.7 (119.9, 223.4)
HPV 33
Day 1 4702 < 4 ( < 4, < 4) 248 24.9 (22.1, 28.0)
Month 3 937 287.8 (272.9, 303.5) 50 647.0 (459.2, 911.4)
Month 7 4702 415.9 (405.6, 426.4) 196 660.4 (550.1, 792.9)
Month 12 958 126.2 (119.9, 132.9) 68 372.9 (276.8, 502.4)
Month 24 909 65.3 (61.7, 69.0) 52 243.3 (169.1, 349.8)
Month 36 813 46.8 (44.0, 49.8) 45 184.0 (124.1, 272.9)
Month 42 835 44.3 (41.6, 47.1) 39 172.6 (111.8, 266.5)
HPV 45
Day 1 4792 < 3 ( < 3, < 3) 97 23.7 (20.2, 27.9)
Month 3 956 160.4 (151.7, 169.7) 14 389.1 (197.5, 766.4)
Month 7 4792 252.8 (246.2, 259.6) 76 346.8 (244.3, 492.4)
Month 12 976 69.2 (65.4, 73.3) 18 203.5 (105.3, 393.5)
Month 24 928 33.0 (31.0, 35.0) 13 115.5 (51.6, 258.2)
Month 36 835 22.9 (21.4, 24.4) 11 60.8 (23.7, 155.8)
Month 42 846 21.1 (19.8, 22.5) 13 87.7 (36.9, 208.3)
HPV 52
Day 1 4455 < 3 ( < 3, < 3) 244 22.3 (20.3, 24.6)
Month 3 895 241.3 (229.7, 253.4) 41 877.2 (543.0, 1417.0)
Month 7 4455 379.7 (371.6, 388.0) 199 534.7 (447.2, 639.3)
Month 12 916 118.9 (113.0, 125.0) 53 450.3 (320.3, 633.0)
Month 24 867 57.9 (54.7, 61.2) 40 265.6 (175.1, 402.8)
Month 36 777 47.9 (45.0, 50.9) 34 177.7 (120.2, 262.8)
Month 42 791 43.2 (40.6, 46.0) 33 178.0 (120.8, 262.3)
(continued on next page)
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to the 9vHPV vaccine based on the demonstration of non-inferior HPV
6/11/16/18 antibody responses. In additional analyses, both qHPV
and 9vHPV vaccine were found to be highly eﬃcacious against
infection and disease in subgroups of young women 16–26 years of
age diﬀering by age, race, and region of residence [29–35] . Therefore,
the small diﬀerences in 9vHPV vaccine immunogenicity by age, race or
region of residence shown in this report in young women 16–26 years
of age are unlikely to have a clinical signiﬁcance.
As seen in this report, anti-HPV GMTs at month 7 are substantially
higher in all subgroups of girls and boys 9–15 years of age deﬁned by
age, race, and region of residence compared with HPV antibody
responses in young women 16–26 years of age in the combined
database (Table 3) or previously reported in study 001 [10]. As
previously reported, prophylactic administration of the 9vHPV vaccine
to 16–26-year-olds was highly eﬀective in preventing infection and
disease due to vaccine HPV types [10]. Thus, the anti-HPV responses
generated by the vaccine in adolescents were suﬃcient to induce high-
level protective eﬃcacy. Overall, 9vHPV vaccine eﬃcacy can be inferred
in all subgroups and the small diﬀerences in 9vHPV vaccine immuno-
genicity by age, race or region of residence shown in this report are
unlikely to have a clinical signiﬁcance in girls and boys 9–15 years of
age.
There are several limitations to this combined analysis of immu-
nogenicity. Even though the studies included in these analyses enrolled
subjects from six continents, they enrolled only a limited number of
subjects from Africa and South Asia. Therefore, it will be important to
further evaluate the immunogenicity of the 9vHPV vaccine in these
regions, especially given the prevalence of HIV infection or other co-
infections and malnutrition in these regions which may impact
immune response to the vaccine. Of note, studies of the qHPV vaccine
in sub-Saharan Africa, India, and Vietnam, and a study in HIV-infected
children demonstrated robust immunogenicity in these populations
[36–39]. Given that the 9vHPV vaccine and qHPV vaccine have
comparable immunogenicity proﬁles [10–12], similar results are
expected with the 9vHPV vaccine.
This combined analysis assessed the immunogenicity of a 3-dose
regimen of 9vHPV vaccine. The use of an alternative 2-dose regimen
for HPV vaccines has been recommended in 2014 by the World Health
Organization in 9- to 14-year-olds [40]. The 2-dose schedule for the
previously developed bivalent and quadrivalent HPV vaccines has been
implemented in several countries [41]. A Phase III study to assess a 2-
dose regimen of the 9vHPV vaccine in girls and boys 9–14 years of age
has recently provided relevant immunogenicity data [42].
In summary, the 9vHPV vaccine induced robust HPV antibody
responses to all 9 vaccine HPV types in subjects from all ages, races,
and geographic regions represented in the aforementioned ﬁve Phase
III studies of the vaccine. This comprehensive immunogenicity proﬁle
provides compelling evidence for administration of the 9vHPV vaccine
at an early age (i.e., before exposure to HPV) and supports a wide-
spread 9vHPV vaccination program regardless of race or region of
residence.
5. Conclusion
In clinical trials, the 9vHPV vaccine was highly immunogenic in
subjects aged 9–26 years. The 9vHPV vaccine immunogenicity was
robust among subjects with diﬀering baseline characteristics (age,
gender, race, region of residence, and HPV serostatus and PCR status
at day 1). Its immunogenicity proﬁle was similar to that of the qHPV
vaccine. The demonstrated eﬃcacy, safety and immunogenicity proﬁle
of the 9vHPV vaccine supports widespread vaccination programs.
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